JP2014523408A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014523408A5 JP2014523408A5 JP2014514023A JP2014514023A JP2014523408A5 JP 2014523408 A5 JP2014523408 A5 JP 2014523408A5 JP 2014514023 A JP2014514023 A JP 2014514023A JP 2014514023 A JP2014514023 A JP 2014514023A JP 2014523408 A5 JP2014523408 A5 JP 2014523408A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- variable region
- sequence
- chain comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims 9
- 238000006467 substitution reaction Methods 0.000 claims 9
- 230000037430 deletion Effects 0.000 claims 8
- 238000012217 deletion Methods 0.000 claims 8
- 230000037431 insertion Effects 0.000 claims 8
- 238000003780 insertion Methods 0.000 claims 8
- 208000026278 immune system disease Diseases 0.000 claims 4
- 238000013508 migration Methods 0.000 claims 3
- 230000005012 migration Effects 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims 1
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 claims 1
- 101000867983 Homo sapiens C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 206010057249 Phagocytosis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000002860 competitive effect Effects 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 238000000670 ligand binding assay Methods 0.000 claims 1
- 230000008782 phagocytosis Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11168787.7 | 2011-06-06 | ||
| EP11168787 | 2011-06-06 | ||
| US201161505137P | 2011-07-07 | 2011-07-07 | |
| US61/505,137 | 2011-07-07 | ||
| EP12159172.1 | 2012-03-13 | ||
| EP12159172 | 2012-03-13 | ||
| PCT/EP2012/060524 WO2012168199A1 (en) | 2011-06-06 | 2012-06-04 | Therapeutic antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016237458A Division JP6416177B2 (ja) | 2011-06-06 | 2016-12-07 | 治療抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014523408A JP2014523408A (ja) | 2014-09-11 |
| JP2014523408A5 true JP2014523408A5 (enExample) | 2015-07-23 |
| JP6141834B2 JP6141834B2 (ja) | 2017-06-07 |
Family
ID=47295509
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014514023A Active JP6141834B2 (ja) | 2011-06-06 | 2012-06-04 | 治療抗体 |
| JP2016237458A Active JP6416177B2 (ja) | 2011-06-06 | 2016-12-07 | 治療抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016237458A Active JP6416177B2 (ja) | 2011-06-06 | 2016-12-07 | 治療抗体 |
Country Status (16)
| Country | Link |
|---|---|
| US (7) | US8613926B2 (enExample) |
| EP (3) | EP3424953B1 (enExample) |
| JP (2) | JP6141834B2 (enExample) |
| KR (1) | KR101978757B1 (enExample) |
| CN (1) | CN103596982B (enExample) |
| AU (1) | AU2012266487B2 (enExample) |
| BR (1) | BR112013031198B1 (enExample) |
| CA (1) | CA2838497C (enExample) |
| DK (3) | DK3798230T3 (enExample) |
| ES (2) | ES2693647T3 (enExample) |
| IL (1) | IL229254A (enExample) |
| PL (2) | PL3424953T3 (enExample) |
| PT (1) | PT3424953T (enExample) |
| RU (1) | RU2616881C2 (enExample) |
| TW (1) | TWI564305B (enExample) |
| WO (1) | WO2012168199A1 (enExample) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3424953T3 (pl) | 2011-06-06 | 2021-01-25 | Novo Nordisk A/S | Lecznicze przeciwciała |
| US9657105B2 (en) * | 2013-03-15 | 2017-05-23 | City Of Hope | CD123-specific chimeric antigen receptor redirected T cells and methods of their use |
| ES2927567T3 (es) | 2013-09-13 | 2022-11-08 | Beigene Switzerland Gmbh | Anticuerpos anti-PD1 y su uso como productos terapéuticos y de diagnóstico |
| EP3626748A1 (en) * | 2014-01-13 | 2020-03-25 | Stephen J. Forman | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| WO2015140591A1 (en) * | 2014-03-21 | 2015-09-24 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
| CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| EP3171892B1 (en) | 2014-07-22 | 2021-11-24 | Apollomics Inc. | Anti-pd-1 antibodies |
| CN110964108B (zh) | 2014-08-05 | 2023-07-07 | 中美冠科生物技术（太仓）有限公司 | 抗pd-l1抗体 |
| US20170328898A1 (en) * | 2014-10-31 | 2017-11-16 | Cell Trend GmbH | Diagnosis of an autoimmune disease using detection of antibodies directed against c5a-receptor |
| ES2909973T3 (es) * | 2015-11-04 | 2022-05-10 | Hope City | Receptores quiméricos para el antígeno que se dirigen a HER2 |
| AU2016359790A1 (en) * | 2015-11-23 | 2018-06-21 | Innate Pharma | CD39 vascular isoform targeting agents |
| MX2018006385A (es) | 2015-11-25 | 2019-09-11 | Visterra Inc | Moleculas de anticuerpo contra april y usos de las mismas. |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| AR107505A1 (es) | 2016-01-22 | 2018-05-09 | Merck Sharp & Dohme | Anticuerpos anti-factor de la coagulación xi |
| KR102218714B1 (ko) | 2016-06-14 | 2021-02-24 | 머크 샤프 앤드 돔 코포레이션 | 항응고 인자 xi 항체 |
| CN109475536B (zh) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | 用于治疗癌症的PD-l拮抗剂和RAF抑制剂的组合 |
| CA3034326A1 (en) | 2016-08-19 | 2018-02-22 | Beigene, Ltd. | Use of a combination comprising a btk inhibitor for treating cancers |
| WO2018137681A1 (en) | 2017-01-25 | 2018-08-02 | Beigene, Ltd. | Crystalline forms of (s) -7- (1- (but-2-ynoyl) piperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahy dropyrazolo [1, 5-a] pyrimidine-3-carboxamide, preparation, and uses thereof |
| CN110382544B (zh) | 2017-03-16 | 2023-12-22 | 先天制药公司 | 用于治疗癌症的组合物和方法 |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| JP7762498B2 (ja) * | 2017-05-25 | 2025-10-30 | ブリストル－マイヤーズ スクイブ カンパニー | 修飾重鎖定常領域を含む抗体 |
| KR102757960B1 (ko) | 2017-06-26 | 2025-01-22 | 베이진 엘티디 | 간세포암(hepatocellular carcinoma: HCC)에 대한 면역 치료 |
| WO2019034580A1 (en) * | 2017-08-14 | 2019-02-21 | Morphosys Ag | HUMANIZED ANTIBODIES FOR CD3 |
| WO2019092148A1 (en) * | 2017-11-10 | 2019-05-16 | Innate Pharma | Antibodies with functionalized glutamine residues |
| WO2019108795A1 (en) | 2017-11-29 | 2019-06-06 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive b-cell lymphomas using a combination comprising btk inhibitors |
| US20190300610A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Pte. Ltd. | Vista antigen-binding molecules |
| AU2019289646B2 (en) | 2018-06-18 | 2025-10-23 | Innate Pharma | Compositions and methods for treating cancer |
| IL281594B1 (en) | 2018-09-17 | 2025-10-01 | Abcuro Inc | Antibodies against KLRG1 |
| US20220041719A1 (en) * | 2018-12-05 | 2022-02-10 | Morphosys Ag | Multispecific antigen-binding molecules |
| KR20210141988A (ko) * | 2019-03-14 | 2021-11-23 | 모르포시스 아게 | C5ar을 표적으로 하는 항체 |
| MX2022006670A (es) * | 2019-12-03 | 2023-03-17 | Shanghai Jiao Tong Univ School Of Medicine | Region fc de anticuerpo teniendo mayor afinidad de union al fcyriib. |
| TWI869528B (zh) * | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| GB2595299B (en) * | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
| WO2022033981A1 (en) | 2020-08-12 | 2022-02-17 | Innate Pharma | Subcutaneous anti-c5ar antagonist treatment regimen with avdoralimab |
| US20230374147A1 (en) | 2020-11-02 | 2023-11-23 | Hummingbird Bioscience Pte. Ltd. | Bcma/taci antigen-binding molecules |
| EP4277931A1 (en) | 2021-01-13 | 2023-11-22 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| MX2023010567A (es) | 2021-03-12 | 2023-09-21 | Genmab As | Variantes de anticuerpos no activadoras. |
| TW202328196A (zh) | 2021-09-16 | 2023-07-16 | 新加坡商蜂鳥生物科技私人有限公司 | 使用vista抗原結合分子的癌症之治療及預防 |
| WO2023046979A1 (en) | 2021-09-27 | 2023-03-30 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| IL311805A (en) | 2021-10-08 | 2024-05-01 | Genmab As | Antibodies that bind to CD30 and CD3 |
| US20250145730A1 (en) * | 2021-12-16 | 2025-05-08 | Shanghai Bao Pharmaceuticals Co., Ltd. | Anti-immunoglobulin degrading enzyme-digested fc variant |
| TW202409280A (zh) | 2022-07-08 | 2024-03-01 | 新加坡科技研究局 | Cnx抗原結合分子 |
| EP4577578A1 (en) | 2022-08-22 | 2025-07-02 | Abdera Therapeutics Inc. | Dll3 binding molecules and uses thereof |
| WO2024062073A1 (en) | 2022-09-22 | 2024-03-28 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| GB202218388D0 (en) | 2022-12-07 | 2023-01-18 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| EP4646233A1 (en) | 2023-01-03 | 2025-11-12 | Hummingbird Bioscience Pte. Ltd. | Her3-binding antibody-drug conjugate |
| WO2024146959A1 (en) | 2023-01-06 | 2024-07-11 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| CN121002069A (zh) | 2023-01-06 | 2025-11-21 | 泰温治疗私人有限公司 | 抗原结合分子 |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
| GB202311050D0 (en) | 2023-07-19 | 2023-08-30 | Vvb Bio Pte Ltd | GP130 antigen-binding molecules |
| WO2025125495A1 (en) | 2023-12-13 | 2025-06-19 | Hummingbird Bioscience Pte. Ltd. | Treatment and prevention of cancer using vista antigen-binding molecules |
| WO2025133322A1 (en) | 2023-12-22 | 2025-06-26 | Agency For Science, Technology And Research | Cnx antigen-binding molecules |
| GB202405551D0 (en) | 2024-04-19 | 2024-06-05 | Vvb Bio Pte Ltd | Combination treatment |
| GB202408044D0 (en) | 2024-06-06 | 2024-07-24 | Vvb Bio Pte Ltd | gp130 antigen-binding molecules |
| WO2025257350A1 (en) | 2024-06-13 | 2025-12-18 | Singapore Health Services Pte Ltd | Pai-1 antigen-binding molecules |
| EP4670793A1 (en) | 2024-06-24 | 2025-12-31 | Montis Biosciences BV | C1Q ANTIGEN BINDING MOLECULES |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4568649A (en) | 1983-02-22 | 1986-02-04 | Immunex Corporation | Immediate ligand detection assay |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0279582A3 (en) | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| JPH02262599A (ja) | 1989-01-03 | 1990-10-25 | Merck & Co Inc | ヒト多形核白血球からの精製Ｃ５ａレセプター |
| CA2062795A1 (en) | 1989-06-29 | 1990-12-30 | Michael W. Fanger | Bispecific reagents for aids therapy |
| US5633076A (en) | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5284746A (en) | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
| US5194594A (en) | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| EP1550729B1 (en) | 1992-09-25 | 2009-05-27 | Avipep Pty Limited | Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| US5480974A (en) | 1993-06-18 | 1996-01-02 | The Scripps Research Institute | Antibodies to human C5a receptor |
| US5827690A (en) | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5861272A (en) | 1995-06-02 | 1999-01-19 | Human Genome Sciences, Inc. | C5A receptor |
| US20010036650A1 (en) | 1994-08-16 | 2001-11-01 | Human Genome Sciences, Inc. | C5a receptor |
| JPH08109200A (ja) | 1994-08-19 | 1996-04-30 | Takeda Chem Ind Ltd | 抗Ｃ５ａレセプター抗体、その製造法および用途 |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| AU718311B2 (en) | 1995-06-05 | 2000-04-13 | Incyte Pharmaceuticals, Inc. | A C5a-like seven transmembrane receptor |
| CA2616914C (en) | 1996-12-03 | 2012-05-29 | Abgenix, Inc. | Egfr-binding antibody |
| JP2001511645A (ja) | 1997-01-31 | 2001-08-14 | インサイト・ファーマスーティカルズ・インコーポレイテッド | ヒトＣ５ａ様受容体 |
| EP0979102A4 (en) | 1997-04-30 | 2005-11-23 | Enzon Inc | DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE |
| US8007798B2 (en) | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| AU2002231194A1 (en) | 2000-11-07 | 2002-05-21 | Genetics Institute, Llc | G protein-coupled receptor protein and nucleic acid molecules and uses therefor |
| EP1409646B1 (en) | 2000-12-19 | 2012-06-13 | Altor BioScience Corporation | Transgenic animals comprising a humanized immune system |
| WO2002061087A2 (en) | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TWI327597B (en) * | 2001-08-01 | 2010-07-21 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| CN100391537C (zh) | 2001-08-17 | 2008-06-04 | 建南德克公司 | 结合至c5和c5a但不阻止c5b形成的补体途径抑制剂 |
| EP1438325B1 (en) | 2001-09-27 | 2009-12-30 | Merck & Co., Inc. | Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
| US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| EP2371861B1 (en) | 2002-01-25 | 2017-08-09 | Novo Nordisk A/S | Monoclonal antibodies against extracellular loops of C5aR |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| WO2004040000A2 (en) | 2002-09-09 | 2004-05-13 | Nura, Inc | G protein coupled receptors and uses thereof |
| AU2002952086A0 (en) | 2002-10-16 | 2002-11-07 | The University Of Queensland | Treatment of osteoarthritis |
| US7285269B2 (en) * | 2002-12-02 | 2007-10-23 | Amgen Fremont, Inc. | Antibodies directed to tumor necrosis factor |
| US7807389B2 (en) | 2003-03-14 | 2010-10-05 | University Of Rochester | Methods and compositions related to joint inflammation diseases |
| EP1606621B1 (en) | 2003-03-17 | 2008-10-29 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with complement component 5a receptor (c5ar) |
| US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| JP2007534631A (ja) | 2003-10-28 | 2007-11-29 | ノボ ノルディスク アクティーゼルスカブ | ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用 |
| EP1701611B1 (en) | 2003-12-24 | 2011-05-18 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| EP1586583A3 (en) | 2004-04-16 | 2005-11-16 | Alligator Bioscience AB (publ) | Compounds that block C5a complement receptor and their use in therapy |
| IL316252A (en) * | 2005-03-23 | 2024-12-01 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
| WO2007055374A1 (ja) | 2005-11-14 | 2007-05-18 | Mitsubishi Tanabe Pharma Corporation | 骨粗鬆症治療剤 |
| CN101501073A (zh) | 2006-08-22 | 2009-08-05 | G2英弗勒美欣私人有限公司 | 抗体制备方法 |
| US8337852B2 (en) | 2006-08-22 | 2012-12-25 | G2 Inflammation Pty Ltd | Anti-C5aR antibodies with improved properties |
| WO2008030564A2 (en) | 2006-09-08 | 2008-03-13 | Verenium Corporation | Aglycosylated antibodies and methods of making and using those antibodies |
| AU2008314697B2 (en) * | 2007-10-22 | 2013-08-29 | Merck Serono S.A. | Single IFN-beta fused to a mutated lgG Fc fragment |
| CN101970494B (zh) | 2008-02-20 | 2015-01-21 | G2炎症私人有限公司 | 人源化抗-C5aR抗体 |
| US9040507B2 (en) | 2008-06-02 | 2015-05-26 | Novelmed Therapeutics, Inc. | Method for treating inflammatory conditions |
| WO2009151634A1 (en) | 2008-06-12 | 2009-12-17 | The Board Of Trustees Of The Leland Stanford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
| WO2010000864A1 (en) | 2008-07-04 | 2010-01-07 | Novo Nordisk A/S | Method for producing monoclonal antibodies |
| CN102264227B (zh) * | 2008-12-22 | 2014-07-23 | 凯莫森特里克斯股份有限公司 | C5aR拮抗剂 |
| WO2011100477A2 (en) | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| CA2789061A1 (en) | 2010-02-26 | 2011-09-01 | Henrik Parshad | Stable antibody containing compositions |
| BR112012030139A2 (pt) | 2010-05-28 | 2017-06-13 | Novo Nordisk As | composições estáveis de anticorpos de doses múltiplas compreendendo um anticorpo e um preservante |
| WO2012001087A1 (en) * | 2010-06-30 | 2012-01-05 | Novo Nordisk A/S | Antibodies that are capable of specifically binding tissue factor pathway inhibitor |
| US20130183280A1 (en) * | 2010-07-15 | 2013-07-18 | Novo Nordisk A/S | Stabilized factor viii variants |
| CA2822288A1 (en) * | 2010-12-22 | 2012-06-28 | Medimmune, Llc | Anti-c5/c5a/c5adesr antibodies and fragments |
| PL3424953T3 (pl) * | 2011-06-06 | 2021-01-25 | Novo Nordisk A/S | Lecznicze przeciwciała |
| CN105392803B (zh) | 2013-05-08 | 2019-12-06 | 诺和诺德股份有限公司 | C5aR拮抗剂的用途 |
-
2012
- 2012-06-04 PL PL18175085T patent/PL3424953T3/pl unknown
- 2012-06-04 EP EP18175085.2A patent/EP3424953B1/en active Active
- 2012-06-04 AU AU2012266487A patent/AU2012266487B2/en not_active Ceased
- 2012-06-04 ES ES12725447.2T patent/ES2693647T3/es active Active
- 2012-06-04 BR BR112013031198-3A patent/BR112013031198B1/pt active IP Right Grant
- 2012-06-04 DK DK20187662.0T patent/DK3798230T3/da active
- 2012-06-04 CA CA2838497A patent/CA2838497C/en active Active
- 2012-06-04 PL PL12725447T patent/PL2718322T3/pl unknown
- 2012-06-04 EP EP12725447.2A patent/EP2718322B1/en active Active
- 2012-06-04 KR KR1020137034239A patent/KR101978757B1/ko active Active
- 2012-06-04 DK DK12725447.2T patent/DK2718322T3/en active
- 2012-06-04 RU RU2013155029A patent/RU2616881C2/ru active
- 2012-06-04 PT PT181750852T patent/PT3424953T/pt unknown
- 2012-06-04 WO PCT/EP2012/060524 patent/WO2012168199A1/en not_active Ceased
- 2012-06-04 CN CN201280028064.1A patent/CN103596982B/zh active Active
- 2012-06-04 ES ES20187662T patent/ES2929575T3/es active Active
- 2012-06-04 DK DK18175085.2T patent/DK3424953T3/da active
- 2012-06-04 EP EP20187662.0A patent/EP3798230B1/en active Active
- 2012-06-04 JP JP2014514023A patent/JP6141834B2/ja active Active
- 2012-06-06 US US13/490,093 patent/US8613926B2/en active Active
- 2012-06-06 TW TW101120198A patent/TWI564305B/zh active
-
2013
- 2013-06-18 US US13/920,585 patent/US8846045B2/en active Active
- 2013-11-05 IL IL229254A patent/IL229254A/en active IP Right Grant
-
2014
- 2014-08-25 US US14/467,393 patent/US20150044231A1/en not_active Abandoned
-
2016
- 2016-11-02 US US15/341,550 patent/US10323097B2/en active Active
- 2016-12-07 JP JP2016237458A patent/JP6416177B2/ja active Active
-
2019
- 2019-06-17 US US16/443,736 patent/US10882916B2/en active Active
-
2020
- 2020-12-18 US US17/127,688 patent/US20210238300A1/en not_active Abandoned
-
2023
- 2023-12-11 US US18/536,032 patent/US20240218076A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014523408A5 (enExample) | ||
| RU2013155029A (ru) | Терапевтические антитела | |
| JP7403505B2 (ja) | Ｃｄ３／ｃｄ３８ ｔ細胞再標的化ヘテロ二量体免疫グロブリン及びその製造方法 | |
| US10618957B2 (en) | Antibody molecules which bind CD79 | |
| JP2014509861A5 (enExample) | ||
| JP2016505556A5 (enExample) | ||
| RU2012151478A (ru) | Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения | |
| HRP20201375T1 (hr) | ANTI-BCMA ANTITIJELA, BISPECIFIČNI ANTIGEN VEŽUĆE MOLEKULE KOJE SE VEŽU ZA BCMA i CD3, I NJIHOVE UPOTREBE | |
| JP2019506363A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| JP2016507523A5 (enExample) | ||
| JP2015533853A5 (enExample) | ||
| HRP20211645T1 (hr) | Molekule za vezanje pd-1 i postupci za njihovu uporabu | |
| JP2011514150A5 (enExample) | ||
| RU2016125489A (ru) | Нейтрализующие моноклональные человеческие антитела против интерлейкина-33 | |
| JP2012530496A5 (enExample) | ||
| RU2011149334A (ru) | Анти-il-17f антитела и способы их применения | |
| JP2012500020A5 (enExample) | ||
| RU2011153932A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К Toll-ПОДОБНЫМ РЕЦЕПТОРАМ 2 И ИХ ПРИМЕНЕНИЯ | |
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| AU2021396247A1 (en) | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function | |
| JP2013519690A5 (enExample) | ||
| AU2021287338B2 (en) | BTLA antibodies | |
| CN116685601A (zh) | 聚集潜在性降低和疏水性降低的改良抗oxMIF抗体 | |
| US20230374148A1 (en) | Binding molecules that multimerise cd45 |